close

Agreements

Date: 2020-02-06

Type of information: Nomination

Compound: chief commercial officer

Company: Vectivbio (Switzerland)

Therapeutic area: Inflammatory diseases - Gastrointestinal diseases - Transplantation

Type agreement: nomination

Action mechanism:

Disease:

Details:

  • On February 6, 2020, VectivBio has appointed Kevin Harris as chief commercial officer. Kevin Harris brings more than 24 years of biopharma leadership experience specializing in the launch and management of specialty products. Prior to VectivBio, Harris was at Incyte for more than 10 years, where he led most of the U.S. commercial functions for the launch of Jakafi® through its first two indications. He also led global product strategy. Previously, Harris held roles of increasing responsibility at Pfizer across the company’s HIV and oncology portfolios. Before that, he served in commercial development and marketing roles at Bristol-Myers Squibb in HIV and oncology. Harris began his career in management consulting and subsequently joined Parexel in a marketing and strategy role. He holds an MBA, with distinction, from Kellogg School of Management at Northwestern University and a B.A. in biology from Cornell University.

Financial terms:

Latest news:

Is general: Yes